Swiss an­ti­body shop Num­ab strikes an im­muno-on­col­o­gy dis­cov­ery deal with Japan’s Ono

Al­most ex­act­ly two years af­ter Intar­cia turned to the Swiss an­ti­body shop Num­ab Ther­a­peu­tics for a sta­ble mul­ti­spe­cif­ic an­ti­body that would fit in­to a once- or twice-year­ly ther­a­py for di­a­betes, the crew at Num­ab are back with an­oth­er care­ful­ly craft­ed dis­cov­ery deal — this time switch­ing fo­cus to im­muno-on­col­o­gy.

Japan’s Ono Phar­ma­ceu­ti­cal turned to Pfäf­fikon, Switzer­land-based Num­ab — in the Schwyz can­ton — to come up with a new, tai­lored an­ti­body that could make a good com­bo with Op­di­vo, the big check­point they are part­nered with Bris­tol-My­ers Squibb on.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.